“Lastly, we expect a fully diluted share count of approximately 56 million shares at year-end.”

In context

“ur growth initiatives and supporting strategic extensions. In this rising interest rate environment, we are also exploring retiring a portion of our debt given our strong cash flow. Now let's turn to our raised outlook for fiscal 2023. For the full year, we now expect net sales growth of approximately 22% to 24% and versus prior year, up from 14% to 16% previously. We expect adjusted EBITDA between $93.5 million to $95 million, up from $83.5 million to $85 million previously. We expect adjusted net income between $59 million to $60.5 million, up from $47 million to $48.5 million previously. And adjusted EPS of $1.07 to $1.10 per diluted share, up from $0.84 to $0.87 previously. We expect our fiscal 2023 adjusted tax rate to be approximately 22% to 23% as compared to 25% to 26% previously. Lastly, we expect a fully diluted share count of approximately 56 million shares at year-end. Let me provide you with additional color on our planning assumptions for fiscal 2023. Starting with the top line. Our raised outlook reflects our outperformance in Q2 relative to our expectations, pipeline related to the incremental space gains Tarang spoke about with Walmart, Target and Shoppers Drug Mart as well as our ongoing business momentum. Turning to gross margin. We now expect our gross margin to be up approximately 175 basis points year-over-year as compared to our previous expectation for up 100 basis points. This is largely a result of our outperformance in Q2 and an improved outlook on transportation costs. In terms of the key drivers for the year, we expect the combination of price increases, margin accretive mix and cost savings to support our gross margin improvement. Now”